Bottom line
SHISX vs PRHSX: the short answer
SHISX (Blackrock Health Sciences Opportunities Portfolio) and PRHSX (T. Rowe Price Health Sciences Fund, Inc.) are both mutual funds.
PRHSX is cheaper at 0.83% vs 1.16% — a difference of $33 a year per $10,000 invested.
Over five years, SHISX returned +5.5% a year vs +4.2% for PRHSX.
Updated Nov 19, 2026
SHISX vs PRHSX side by side
| SHISX | PRHSX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | BlackRock | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.16% | 0.83% |
| Annual cost per $10k | $116 | $83 |
| 10-yr cost on $10k (prospectus) | $1,409 | $1,025 |
| Max front load | — | — |
| 12b-1 fee | 0.25% | — |
| 1-yr return | +15.9% | +17.7% |
| 5-yr return (annualized) | +5.5% | +4.2% |
| 10-yr return (annualized) | +9.5% | +9.1% |
| Best quarter | +17.5% | +23.5% |
| Worst quarter | −11.5% | −15.8% |
| Net assets (fund) | $5.9B | $11.9B |
| Number of holdings | 155 | 279 |
| Portfolio turnover | 49% | 62% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | SHISX | PRHSX | Difference |
|---|---|---|---|
| 2025 | +15.9% | +17.7% | −1.8% |
| 2024 | +3.8% | +1.8% | +2.0% |
| 2023 | +3.5% | +3.1% | +0.4% |
| 2022 | −6.0% | −12.2% | +6.2% |
| 2021 | +11.7% | +13.3% | −1.5% |
| 2020 | +19.4% | +30.1% | −10.7% |
| 2019 | +25.3% | +29.1% | −3.9% |
| 2018 | +8.0% | +1.2% | +6.7% |
| 2017 | +24.8% | +28.0% | −3.2% |
| 2016 | −6.1% | −10.4% | +4.3% |
Source: Fund prospectus bar charts
Holdings overlap
14 of SHISX's top 25 holdings also appear in PRHSX's top 25.
| Holding | SHISX | PRHSX |
|---|---|---|
| Eli Lilly & Company | 12.29% | 14.28% |
| Johnson & Johnson | 8.77% | 6.63% |
| Unitedhealth Group Inc | 6.10% | 5.99% |
| Merck & Company Inc | 4.94% | 4.01% |
| Gilead Sciences Inc | 4.19% | 2.82% |
| Abbvie Inc | 3.94% | 5.10% |
| Amgen Inc | 3.37% | 1.82% |
| Thermo Fisher Scientific Inc | 3.02% | 2.52% |
| Vertex Pharmaceuticals Inc | 2.74% | 2.28% |
| Danaher Corp | 2.00% | 1.43% |
| Abbott Laboratories | 1.97% | 1.89% |
| Intuitive Surgical Inc | 1.95% | 1.87% |
| Elevance Health Inc | 1.56% | 1.53% |
| Stryker Corp | 1.15% | 1.78% |
Source: SEC Form N-PORT
SHISX top 10
- Eli Lilly & Company — 12.29%
- Johnson & Johnson — 8.77%
- Unitedhealth Group Inc — 6.10%
- Merck & Company Inc — 4.94%
- Gilead Sciences Inc — 4.19%
- Abbvie Inc — 3.94%
- Amgen Inc — 3.37%
- Thermo Fisher Scientific Inc — 3.02%
- Vertex Pharmaceuticals Inc — 2.74%
- Pfizer Inc — 2.61%
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
FAQ
What is the difference between SHISX and PRHSX?
Which is cheaper, SHISX or PRHSX?
Should I own both SHISX and PRHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.